Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $36360.0.

  • Dna X's Gains from Investment Securities fell 9510.71% to $36360.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $36360.0, marking a year-over-year decrease of 9510.71%. This contributed to the annual value of $755494.0 for FY2024, which is 4679.08% up from last year.
  • According to the latest figures from Q3 2025, Dna X's Gains from Investment Securities is $36360.0, which was down 9510.71% from $675779.0 recorded in Q2 2025.
  • Dna X's 5-year Gains from Investment Securities high stood at $5.8 million for Q2 2023, and its period low was -$5000.0 during Q4 2023.
  • In the last 5 years, Dna X's Gains from Investment Securities had a median value of $675779.0 in 2025 and averaged $1.4 million.
  • The largest annual percentage gain for Dna X's Gains from Investment Securities in the last 5 years was 57282150.0% (2023), contrasted with its biggest fall of 10054.47% (2023).
  • Dna X's Gains from Investment Securities (Quarter) stood at $42000.0 in 2021, then soared by 2085.71% to $918000.0 in 2022, then tumbled by 100.54% to -$5000.0 in 2023, then soared by 8520.0% to $421000.0 in 2024, then tumbled by 91.36% to $36360.0 in 2025.
  • Its Gains from Investment Securities stands at $36360.0 for Q3 2025, versus $675779.0 for Q2 2025 and $720175.0 for Q1 2025.